<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leuprolide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leuprolide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Leuprolide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9549" href="/d/html/9549.html" rel="external">see "Leuprolide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11211" href="/d/html/11211.html" rel="external">see "Leuprolide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187454"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Camcevi;</li>
<li>Eligard;</li>
<li>Fensolvi (6 Month);</li>
<li>Lupron Depot (1-Month);</li>
<li>Lupron Depot (3-Month);</li>
<li>Lupron Depot (4-Month);</li>
<li>Lupron Depot (6-Month);</li>
<li>Lupron Depot-Ped (1-Month);</li>
<li>Lupron Depot-Ped (3-Month);</li>
<li>Lupron Depot-Ped (6-Month)</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867345"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Eligard;</li>
<li>Lupron Depot;</li>
<li>Lupron Depot (1-Month);</li>
<li>Lupron Depot (3-Month);</li>
<li>Lupron Depot 3 Month Kit;</li>
<li>Lupron [DSC];</li>
<li>Zeulide Depot</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048192"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Hormone (Gonadotropin Hormone-Releasing Analog)</span>;</li>
<li>
<span class="list-set-name">Luteinizing Hormone-Releasing Hormone Analog</span></li></ul></div>
<div class="block dop drugH1Div" id="F187468"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Each formulation (including different strengths) has unique release characteristics; do not use partial syringes or a combination of syringes to achieve dose. Dosing regimens and route of administration of international product(s) may vary from US dosage forms; refer to specific international product labeling.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bd49784-37fe-43fb-bf63-92207c0b2eef">Central precocious puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central precocious puberty (CPP):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pubertal maturation will resume within months (eg, ~6 to 18 months) after discontinuation of treatment, with wide variability; consider discontinuing leuprolide therapy at the appropriate age for the onset of puberty (eg, when peers would be experiencing puberty). Therapy is typically discontinued at ~10 to 12 years of age, depending on clinical circumstances (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26668298','lexi-content-ref-31319416','lexi-content-ref-15598675','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26668298','lexi-content-ref-31319416','lexi-content-ref-15598675','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Children:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monthly dosing: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Lupron Depot-Ped (monthly formulation):</p>
<p style="text-indent:-2em;margin-left:10em;">Fixed dosing: IM: 7.5 mg every 4 weeks; titrate as needed to attain adequate suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21798557','lexi-content-ref-31319416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21798557','lexi-content-ref-31319416'])">Ref</a></span>). A lower starting dose of 3.75 mg every 4 weeks is also effective in most children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7788009','lexi-content-ref-31347350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7788009','lexi-content-ref-31347350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Weight-directed dosing: <b>Note:</b> Although weight-directed dosing is described by the manufacturer, some experts recommend against this approach for depot formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31319416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31319416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">≤25 kg: IM: 7.5 mg every 4 weeks; titrate dose in 3.75 mg increments (ie, to the next available dosage form size) every 4 weeks until clinical or laboratory tests indicate adequate suppression.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;25 to 37.5 kg: IM: 11.25 mg every 4 weeks; titrate dose in 3.75 mg increments (ie, to the next available dosage form size) every 4 weeks until clinical or laboratory tests indicate adequate suppression.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;37.5 kg: IM: 15 mg every 4 weeks; titrate dose in 3.75 mg increments (ie, to the next available dosage form size) every 4 weeks until clinical or laboratory tests indicate adequate suppression.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Every-3-month dosing</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Lupron Depot-Ped (3-month formulation) and Lupron Depot: IM: 11.25 mg, 22.5 mg, or 30 mg every 12 weeks. <b>Note:</b> If initiating therapy with the 3-month formulation, some experts begin with 11.25 mg dose and titrate to attain adequate suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21798557','lexi-content-ref-24926950','lexi-content-ref-19302581','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21798557','lexi-content-ref-24926950','lexi-content-ref-19302581','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Every-6-month dosing: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Lupron Depot-Ped (6-month formulation): IM: 45 mg every 24 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37334213','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37334213','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Children ≥2 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Long-acting formulation:</i> Fensolvi: SUBQ: 45 mg every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37334213','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37334213','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Short-acting formulation:</i> Leuprolide acetate 5 mg/mL solution: SUBQ: Initial: 50 <b>mcg</b>/kg/dose once daily; may titrate dose upward by 10 <b>mcg</b>/kg/day if suppression is not adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lupron.2017.05']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lupron.2017.05'])">Ref</a></span>).<b> Note:</b> Dosage form is no longer approved for this indication; use has been replaced by long-acting formulations which require less frequent dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31319416','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31319416','lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to ongoing growth and bone maturation in adolescents, leuprolide use in patients &lt;18 years of age should be reserved for patients with pain refractory to conservative surgical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30461694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30461694'])">Ref</a></span>); empiric therapy should not be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18936548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18936548'])">Ref</a></span>). Although the manufacturer's labeling suggest monotherapy with leuprolide as an option for initial courses, experts suggest that in adolescents, initial leuprolide therapy be in combination with norethindrone with or without conjugated estrogen (add-back therapy). Adolescent patients should also be supplemented with calcium and vitamin D (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30461694','lexi-content-ref-18936548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30461694','lexi-content-ref-18936548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot (monthly formulation): Post-menarche adolescents: IM: 3.75 mg every month for up to 6 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot (3-month formulation): Post-menarche adolescents: IM: 11.25 mg every 3 months for up to 2 doses as initial therapy; for retreatment, may repeat course for up to 2 doses; total treatment duration should not exceed 12 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0eef3df9-b145-45b3-8613-805cd4eeb52a">Leuprolide Stimulation Test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leuprolide (GnRHa) Stimulation Test (Female):</b> Limited data available: Children ≥2 years: Leuprolide acetate 5 mg/mL solution: SUBQ: 20 <b>mcg</b>/kg once; measure LH and follicle-stimulating hormone at baseline and after administration (usually 2 spaced measurements ≤120 minutes [eg, 30 and 60 minutes <b>or</b> 60 and 120 minutes]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19189683','lexi-content-ref-20184599','lexi-content-ref-21489559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19189683','lexi-content-ref-20184599','lexi-content-ref-21489559'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc7d04bc-1f23-48c1-bc9d-91bf6a311bb0">Uterine leiomyomata</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine leiomyomata (fibroids):</b>
<b>Note:</b> Use in combination with iron supplementation. Due to ongoing growth and bone maturation in adolescents, consider calcium and vitamin D supplementation with therapy based on experience in adolescents with leuprolide use for endometriosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot (monthly formulation): Post-menarche adolescents: IM: 3.75 mg every month for up to 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot (3-month formulation): Post-menarche adolescents: IM: 11.25 mg as a single injection.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Delayed hypersensitivity (including severe cutaneous adverse reactions of Stevens-Johnson syndrome and toxic epidermal necrolysis): Discontinue future leuprolide therapy at first signs/symptoms of a delayed hypersensitivity reaction and manage as clinically indicated.</p></div>
<div class="block dorp drugH1Div" id="F51117824"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51117825"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F187456"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9549" href="/d/html/9549.html" rel="external">see "Leuprolide: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>:</b> Do not use a fractional dose of the 3-, 4-, or 6-month depot formulation, or a combination of doses of the monthly depot formulation or any depot formulation due to different release characteristics. Do not use a combination of syringes to achieve a particular dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef12445f-5450-4468-80d0-329501655968">Breast cancer in male patients, hormone receptor–positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in male patients, hormone receptor–positive (off-label use): Note: </b>Should be used in combination with an aromatase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adva</i>
<i>nced or metastatic disease:</i>
<b> IM:</b> 3.75 mg once every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25980944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25980944'])">Ref</a></span>). Endocrine therapy for males with advanced or metastatic, HR+, HER2-negative breast cancer may be sequenced as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1e555bb-6651-4aad-b33a-f9fa6ef1eda7">Breast cancer, premenopausal ovarian suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, premenopausal ovarian suppression (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot: <b>IM:</b> 3.75 mg every 28 days for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10321505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10321505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot-3 month: <b>IM: </b>11.25 mg every 3 months for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10321505','lexi-content-ref-17577027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10321505','lexi-content-ref-17577027'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b>
<b>Note:</b> Initial treatment (maximum 6 months) may be as monotherapy or combination therapy with norethindrone acetate (add-back therapy). A single retreatment course (maximum 6 months) of leuprolide in combination with norethindrone acetate may be considered if symptoms recur. Monotherapy is not recommended for retreatment. Total duration of therapy (initial plus re-treatment for symptom recurrence) should not exceed 12 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial therapy: May be used as monotherapy or in combination with norethindrone acetate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot:</i>
<b>IM:</b> 3.75 mg every month for up to 6 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot-3 month:</i>
<b>IM: </b>11.25 mg every 3 months for 1 to 2 doses (maximum 6 months).</p>
<p style="text-indent:-2em;margin-left:4em;">Symptom recurrence: Administer in combination with norethindrone acetate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot:</i>
<b>IM: </b>3.75 mg every month for up to 6 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot-3 month:</i>
<b>IM: </b>11.25 mg every 3 months for 1 to 2 doses (maximum 6 months).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77f3beb6-ef12-4d8d-92ff-3a67049ecce5">Hormone therapy for transgender females, assigned male at birth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hormone therapy for transgender females, assigned male at birth (adjunctive agent) (off-label use): IM (depot) or SUBQ:</b> 3.75 mg monthly or 11.25 mg every 3 months in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320642','lexi-content-ref-26932202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320642','lexi-content-ref-26932202'])">Ref</a></span>). <b>Lupron Depot</b> should be administered IM and <b>Eligard </b>should be administered SUBQ.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c307a68d-aa90-4809-92e4-ae972fb30608">Paraphilia, males</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paraphilia, males (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May cause an initial increase in androgen concentrations; concomitant antiandrogen therapy (eg, cyproterone, flutamide) is recommended starting 1 week before and continued for the first month after leuprolide initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19243704','lexi-content-ref-32452729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19243704','lexi-content-ref-32452729'])">Ref</a></span>). Avoid use in patients with osteoporosis (especially in patients with prior fracture) or active pituitary disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19243704','lexi-content-ref-10986575','lexi-content-ref-32452729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19243704','lexi-content-ref-10986575','lexi-content-ref-32452729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial test dose: SUBQ:</b> 1 mg once; if no hypersensitivity to the test dose, may proceed to treatment dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19243704','lexi-content-ref-10986575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19243704','lexi-content-ref-10986575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Treatment dosing: Depot IM:</b> 3.75 to 7.5 mg monthly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19243704','lexi-content-ref-10986575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19243704','lexi-content-ref-10986575'])">Ref</a></span>) <b>or</b> 11.25 mg every 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32452729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32452729'])">Ref</a></span>). If therapy is discontinued, rebound elevation in testosterone levels and recurrence of symptoms may occur; if symptoms recur, retreatment with leuprolide or another agent is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32452729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32452729'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13531fc0-f759-4ce8-adf1-0f2fb51f128a">Prostate cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b>
<b>Note:</b> Treatment is usually continued after development of metastatic (castration-resistant) disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Leuprolide acetate:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot 7.5 mg (monthly):</i>
<b>IM:</b> 7.5 mg every month.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Leuprolide Depot (generic, Cipla), Lupron Depot 22.5 mg (3 month):</i>
<b>IM: </b>22.5 mg every 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot 30 mg (4 month):</i>
<b>IM: </b>30 mg every 16 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lupron Depot 45 mg (6 month):</i>
<b>IM: </b>45 mg every 24 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Eligard:</i>
<b>SUBQ:</b> 7.5 mg monthly <b>or</b> 22.5 mg every 3 months <b>or</b> 30 mg every 4 months <b>or</b> 45 mg every 6 months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Leuprolide acetate 5 mg/mL solution:</i>
<b>SUBQ:</b> 1 mg daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Zeulide Depot [Canadian product]:</i>
<b>IM: </b>3.75 mg once every month <b>or</b> 22.5 mg once every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Leuprolide mesylate:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Camcevi: <b>SUBQ:</b></i>42 mg leuprolide (equivalent to ~48 mg leuprolide mesylate) once every 6 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc7d04bc-1f23-48c1-bc9d-91bf6a311bb0">Uterine leiomyomata</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uterine leiomyomata (fibroids):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Prior to combination therapy with iron, consider a 1-month trial period of iron alone; the addition of leuprolide may be considered when response to iron monotherapy is inadequate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lupron Depot:</i>
<b>IM:</b> 3.75 mg every month for up to 3 months (in combination with iron).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lupron Depot-3 month:</i>
<b>IM:</b> 11.25 mg as a single injection (in combination with iron).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991276"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988572"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56415987"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Decreased bone density</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Leuprolide may cause <b>decreased bone mineral density </b>(BMD). Data in pediatric patients with central precocious puberty are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Heger.1999','lexi-content-ref-26360682','lexi-content-ref-17964961']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Heger.1999','lexi-content-ref-26360682','lexi-content-ref-17964961'])">Ref</a></span>). Data from use of gonadotropin-releasing hormone (GnRH) agonist therapy in males with prostate cancer show a 2% to 3% decrease in BMD of the hip and spine per year during initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062721'])">Ref</a></span>). Postmarketing claim-based studies show a <b>bone fracture</b> rate of 19.4% in males with prostate cancer receiving androgen deprivation therapy compared to 12.6% to those not receiving therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15647578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15647578'])">Ref</a></span>). Bone loss with GnRH agonist therapy in females is less quantified but described as significant and may exceed 1% per month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7750585','lexi-content-ref-9660431']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7750585','lexi-content-ref-9660431'])">Ref</a></span>). In adult females, discontinuation of therapy did not ensure complete recovery of the bone loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7750585','lexi-content-ref-22028996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7750585','lexi-content-ref-22028996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; fundamentally, it is the increase in bone turnover and decrease in BMD that causes adverse skeletal effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26360682','lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26360682','lexi-content-ref-17062721'])">Ref</a></span>). The imbalance of osteoclast and osteoblast activity is secondary to parathyroid hormone, estrogen, and other sex hormone level changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26360682','lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26360682','lexi-content-ref-17062721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; remarkable bone loss may occur after 3 to 6 months of GnRH agonist therapy but is more commonly associated with long-term GnRH therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26360682','lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26360682','lexi-content-ref-17062721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15647578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15647578'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of osteoporosis</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of medications associated with bone loss (eg, antiseizure medications, long-term corticosteroids, aromatase inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863451','lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863451','lexi-content-ref-17062721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lifestyle factors (eg, chronic tobacco or alcohol use, sedentary nature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low calcium intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin D deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypogonadism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062721'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions (<b>urticaria</b>, <b>angioedema</b>, <b>anaphylaxis</b>) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22050405','lexi-content-ref-31972562','lexi-content-ref-21233692','lexi-content-ref-25719301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22050405','lexi-content-ref-31972562','lexi-content-ref-21233692','lexi-content-ref-25719301'])">Ref</a></span>). Recurrent anaphylaxis in response to depot leuprolide has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1923237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1923237'])">Ref</a></span>); with recurrent anaphylaxis or a history of anaphylaxis to multiple unrelated drugs (eg, leuprolide acetate depot and triamcinolone), a reaction to the excipient carboxymethylcellulose should be considered. Delayed hypersensitivity reactions have also been reported, including maculopapular <b>skin rash</b>, mycosis-fungoides-like eruption, <b>serum sickness</b>, and <b>hypersensitivity angiitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24918569','lexi-content-ref-20470239','lexi-content-ref-21233692','lexi-content-ref-22568476','lexi-content-ref-22882386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24918569','lexi-content-ref-20470239','lexi-content-ref-21233692','lexi-content-ref-22568476','lexi-content-ref-22882386'])">Ref</a></span>). <b>Injection site granuloma</b> may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17445679','lexi-content-ref-28919272','lexi-content-ref-15888168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17445679','lexi-content-ref-28919272','lexi-content-ref-15888168'])">Ref</a></span>). <b>Bullous dermatitis</b>, <b>erythema multiforme</b>, <b>exfoliative dermatitis</b>, <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Non–dose-related; likely immunologic (ie, IgE mediated, with specific antibodies formed against a drug allergen following initial exposure) or due to histamine-releasing activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31972562','lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31972562','lexi-content-ref-30275849'])">Ref</a></span>). In addition, leuprolide appears to be a peptide ligand for MRGPRX2 receptor on mast cells and a cause for non-IgE–mediated mast cell activation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25517090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25517090'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Non–dose-related; immunologic (involving a T-cell–mediated drug-specific immune response or immune complex-mediated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-20470239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-20470239'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Granuloma: Non–dose-related; may be caused by a foreign-body reaction against polymers used as a vehicle for leuprolide injection or a reaction to leuprolide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28919272','lexi-content-ref-22882386','lexi-content-ref-17878701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28919272','lexi-content-ref-22882386','lexi-content-ref-17878701'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration but may occur up to 14 days after injection of the depot (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-22050405','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-22050405','lexi-content-ref-NICE.2014'])">Ref</a></span>). Reactions have occurred with the first injection up to the 25<sup>th</sup> injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31972562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31972562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Varied; typically occur days to 6 weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20470239','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20470239','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Granulomas: Delayed; usually appear weeks to months after injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28919272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28919272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity with other gonadotropin-releasing hormone analogues, including triptorelin and goserelin, may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31972562','lexi-content-ref-17125443','lexi-content-ref-21233692','lexi-content-ref-25719301','lexi-content-ref-17878701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31972562','lexi-content-ref-17125443','lexi-content-ref-21233692','lexi-content-ref-25719301','lexi-content-ref-17878701'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Leuprolide acetate depot contains both carboxymethylcellulose (carmellose in Australia/Asia, E466 in Europe) and polysorbate 80, which are excipients that have independently been associated with anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33737254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33737254'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Metabolic changes/cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Metabolic changes with androgen deprivation therapy (ADT) are concerning due to increased risk of both arterial and venous thromboembolic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31969015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31969015'])">Ref</a></span>). Gonadotropin releasing hormone (GnRH) agonists, such as leuprolide, may increase risk of a major cardiovascular and cerebrovascular event (20%) vs GnRH antagonists (3%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31188734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31188734'])">Ref</a></span>). Additionally, ischemic heart disease was found to be the most common cardiac disorder in a phase 3 randomized clinical trial with an incidence of 10% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20952020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20952020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; ADT decreases testosterone levels which elicits metabolic changes, such as decreased lean muscle mass, increased visceral fat, insulin resistance, and dyslipidemia, leading to a prothrombotic state that expedites atherosclerosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26831435','lexi-content-ref-31969015','lexi-content-ref-30879969','lexi-content-ref-33896190','lexi-content-ref-16434464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26831435','lexi-content-ref-31969015','lexi-content-ref-30879969','lexi-content-ref-33896190','lexi-content-ref-16434464'])">Ref</a></span>). Immunomodulatory changes, such as activation of atherosclerotic plaque T-cell GnRH receptors leading to plaque destabilization, are also being explored (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; risk increases during the first 6 months of ADT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879969','lexi-content-ref-33896190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879969','lexi-content-ref-33896190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior cardiovascular disease/event or preexisting risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879969','lexi-content-ref-33896190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879969','lexi-content-ref-33896190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30879969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30879969'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pituitary apoplexy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gonadotropin-releasing hormone (GnRH) analogues have rarely been associated with <b>pituitary apoplexy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27586180','lexi-content-ref-28710301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27586180','lexi-content-ref-28710301'])">Ref</a></span>). Presentation is generally a sudden severe headache associated with visual impairment (photophobia, diplopia, or blurry vision), headache, vomiting, hyponatremia, and ophthalmoplegia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jaggi.2019','lexi-content-ref-28710301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jaggi.2019','lexi-content-ref-28710301'])">Ref</a></span>). Immediate care ranging from medical management to surgical invention may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28710301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28710301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose related; pituitary stimulation to underlying adenoma causes ischemic necrosis and subsequent hemorrhage, or compression of vessels may lead to infarction in the nonadenomatous gland (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28710301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28710301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most commonly occurs within hours (&lt;4 hours) of first administration; has also been observed up to 14 days after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jaggi.2019','lexi-content-ref-25455737','lexi-content-ref-28710301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jaggi.2019','lexi-content-ref-25455737','lexi-content-ref-28710301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Elderly males with underlying gonadotropin-secreting adenoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25455737','lexi-content-ref-28710301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25455737','lexi-content-ref-28710301'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of pituitary macroadenoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jaggi.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jaggi.2019'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Leuprolide has rarely been associated with acute <b>mania </b>and <b>psychiatric signs and symptoms</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23930615','lexi-content-ref-21190641','lexi-content-ref-28387484','lexi-content-ref-Pong.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23930615','lexi-content-ref-21190641','lexi-content-ref-28387484','lexi-content-ref-Pong.2014'])">Ref</a></span>). There are very few case reports in the literature; however, the development of such events can require hospitalization and initiation of antidepressants and/or neuroleptic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28387484','lexi-content-ref-Pong.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28387484','lexi-content-ref-Pong.2014'])">Ref</a></span>). Presentation is more common in those without prior history of psychiatric events, but exacerbations of existing pathology have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28387484','lexi-content-ref-Pong.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28387484','lexi-content-ref-Pong.2014'])">Ref</a></span>). In 23% of women taking a gonadotropin-releasing hormone agonist, depression was reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26927501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26927501'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; however, estrogen withdrawal or deficit in central serotonin transmission is postulated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28387484','lexi-content-ref-Pong.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28387484','lexi-content-ref-Pong.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Dose- and time-related; symptoms appear after several injections have been received (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28387484','lexi-content-ref-Pong.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28387484','lexi-content-ref-Pong.2014'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrhythmias</b> associated with leuprolide therapy are very rare with incidence limited to clinical trials until a recent case report of <b>prolonged QT interval on ECG</b> and <b>torsades de pointes </b>(TdP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32782861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32782861'])">Ref</a></span>). In a phase 3 randomized clinical trial, supraventricular arrhythmias occurred in 4% of patients and prolonged QT interval occurred in 1% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20952020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20952020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i> Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Seizures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There are postmarketing reports of <b>seizures</b> with the use of long-acting leuprolide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11033292','lexi-content-ref-23635751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11033292','lexi-content-ref-23635751'])">Ref</a></span>). While most seizures are classified as unspecified, cases of generalized, partial, and absence seizures are noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11033292','lexi-content-ref-23635751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11033292','lexi-content-ref-23635751'])">Ref</a></span>). Reports were mostly in females (average age 25 years) receiving therapy for endometriosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635751'])">Ref</a></span>). There are 2 reports of seizure in pediatric patients with preexisting brain damage; resolution of seizure activity occurred with discontinuation of leuprolide therapy and initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11033292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11033292'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Postulated to be dose-related; related to pharmacological action. Potentially same mechanism as catamenial seizures since leuprolide causes transient increase in hormones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; average onset is 41 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635751'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of catamenial seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635751'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting brain damage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11033292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11033292'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tumor flare</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A <b>tumor flare</b> or transient increase in prostate cancer symptoms, especially in patients with advanced disease, presents as an exacerbation of initial symptoms, such as ureteral obstruction, urinary retention, spinal cord compression, and/or lymphedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>). Sudden death during tumor flare has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2122011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2122011'])">Ref</a></span>). At one time, the incidence was estimated to be as high as 11%; however, advances in screening, earlier treatment, and the concurrent use of antiandrogen therapy have decreased the rate of tumor flare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> An initial increase in testosterone peaks ~3 days after administration, exacerbating symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003','lexi-content-ref-2933122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003','lexi-content-ref-2933122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; symptoms observed within the first 1 to 3 weeks of receiving leuprolide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High prostate-specific antigen levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impending cord compression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Urethral obstruction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986003'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F187421"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults, unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG changes (≤19%), edema (5% to 21%), flushing (children: 5%; adults: ≤78%), hypertension (children, adults: ≤15%), ischemia (≤19%)<span class="lexi-table-link-container"> (<a aria-label="Ischemia table link" class="lexi-table-link" data-table-id="lexi-content-ischemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ischemia')">table 1</a>)</span><span class="table-link" style="display:none;">Ischemia</span>, peripheral edema (children, adults: ≤12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ischemia" frame="border" id="lexi-content-ischemia" rules="all">
<caption>
<b>Leuprolide: Adverse Reaction: Ischemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Leuprolide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Diethylstilbestrol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Leuprolide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Diethylstilbestrol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adult males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">SUBQ injection</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prostate cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "ECG changes/ischemia"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤98%), pruritus (children: 11%; adults: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (3% to 11%), hot flash (≤98%), increased serum cholesterol (23%), increased serum triglycerides (12% to 32%), weight gain (children, adults: ≤13%), weight loss (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children: 9% to 18%; adults: &lt;1%), constipation (children: 6%; adults: ≤14%), diarrhea (children, adults: ≤16%), hematochezia (children: ≤13%), nausea (children: ≤13%; adults: ≤25%), vomiting (children: ≤13%; adults: ≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Testicular atrophy (4% to 20%), vaginitis (children: ≤3%; adults: 11% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (children: ≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (children: ≤78%; adults: 3% to 12%), discomfort at injection site (children: ≤78%; adults: ≤19%), erythema at injection site (children: ≤78%; adults: 2% to 38%), injection-site reaction (children: ≤78%; adults: ≤14%, including abscess at injection site), pain at injection site (children: ≤78%; adults: ≤19%), swelling at injection site (children: ≤78%), warm sensation at injection site (children: ≤78%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (children: &lt;1%; adults: ≤18%), depression (children: ≤22%; adults: ≤31%)<span class="lexi-table-link-container"> (<a aria-label="Depression table link" class="lexi-table-link" data-table-id="lexi-content-depression" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-depression')">table 2</a>)</span><span class="table-link" style="display:none;">Depression</span>, dizziness (children: &lt;1%; adults: ≤16%), emotional lability (children: ≤22%; adults: ≤31%), fatigue (≤18%), headache (children: 2% to 33%; adults: ≤65%), insomnia (children, adults: ≤31%), lethargy (≤13%), malaise (≤18%), migraine (≤65%), mood changes (children: ≤22%; adults: ≤5%), pain (3% to 33%), psychiatric signs and symptoms (children: ≤22%, including affective disorder, aggressive behavior, auditory hallucinations, crying, disruptive mood dysregulation disorder, trichotillomania), sleep disorder (≤31%), vertigo (≤16%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Depression" frame="border" id="lexi-content-depression" rules="all">
<caption style="text-align:center;">
<b>Leuprolide: Adverse Reaction: Depression</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Leuprolide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Danazol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Leuprolide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Danazol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 mg IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Central precocious puberty in children</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as “psychiatric event including depression”</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3.75 mg IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Endometriosis in adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "depression/emotional lability"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3.75 mg IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Endometriosis in adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">31</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "depression/emotional lability"</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3.75 mg IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uterine fibroids in adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "depression/emotional lability"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthropathy (children: &lt;2%; adults: 4% to 16%), increased creatinine phosphokinase in blood specimen, musculoskeletal pain (children: &lt;1%; adults: ≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children, adults: 1% to 13%), epistaxis (children, adults: ≤13%), flu-like symptoms (children: &lt;2%; adults: ≤21%), nasopharyngitis (children, adults: ≤22%), upper respiratory tract infection (children: 6%; adults: ≤21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 13% to 17%; adult: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;5%), angina pectoris (&lt;5%), atrial fibrillation (&lt;5%), bradycardia (children, adults: &lt;5%), cardiac arrhythmia (&lt;5%), chest pain (children: 4%), coronary artery disease (≤6%), deep vein thrombophlebitis (&lt;5%), heart failure (1%), heart murmur (3%), hypotension (children; adults: &lt;5%), palpitations (&lt;5%), peripheral vascular disease (&lt;2%), phlebitis (≤2%), pitting edema (≤5%), syncope (children, adults: &lt;5%), tachycardia (&lt;5%), thrombosis (≤2%), varicose veins (&lt;5%), vasodilation (children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (children: ≤3%; adults: ≤10%), allergic skin reaction (≤10%), alopecia (children, adults: ≤4%), body odor (children, adults: &lt;5%), cellulitis (&lt;5%), cold and clammy skin (4%), dermatitis (5%), ecchymoses (&lt;5%), erythema multiforme (children: ≤3%), hair disease (&lt;5%), hyperhidrosis (children: 4%), hyperpigmentation (including dyschromia: &lt;5%), leukoderma (children: &lt;2%), malignant melanoma, nail disease (children, adults: &lt;5%), night sweats (3%), seborrhea (children: ≤3%), skin carcinoma (including ear: &lt;5%), skin hypertrophy (children: &lt;2%), skin lesion (&lt;5%), skin rash (children, adults: 7%), xeroderma (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Androgen-like effect (females: ≤4%), decreased HDL cholesterol (2% to 10%), decreased serum albumin (≥5%), decreased serum bicarbonate (≥5%), decreased serum total protein (≥5%), dehydration (8%), diabetes mellitus (children; adults: &lt;5%), feminization (children: &lt;2%), goiter (children, adults: &lt;5%), growth retardation (children: &lt;2%), gynecomastia (children, adults: ≤7%), hirsutism (children: &lt;2%), hyperglycemia (≥5%), hyperphosphatemia (≥5%), hyperuricemia (≥5%), hypoglycemia (&lt;5%), increased lactate dehydrogenase (≥5%), increased LDL cholesterol (8%), increased serum calcium (&lt;5%), increased thirst (&lt;5%), increased uric acid (≥5%), loss of libido (&lt;2%), menstrual disease (children, adults: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;5%), anorexia (6%), change in appetite (4%), colitis (≤3%), duodenal ulcer (&lt;5%), dysgeusia (&lt;5%), dyspepsia (children, adults: &lt;4%), dysphagia (children, adults: &lt;5%), eructation (&lt;5%), flatulence (≤4%), gastroenteritis (≤3%), gastrointestinal hemorrhage (&lt;5%), gingival hemorrhage (&lt;5%), gingivitis (children, adults: &lt;5%), hernia of abdominal cavity (&lt;5%), hiccups (&lt;5%), increased appetite (children, adults: &lt;5%), intestinal obstruction (&lt;5%), melanosis (&lt;5%), mucous membrane abnormality (reaction: ≤4%), peptic ulcer (&lt;5%), periodontal abscess (&lt;5%), rectal polyp (&lt;5%), xerostomia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Balanitis (&lt;5%), bladder carcinoma (&lt;5%), bladder spasm (&lt;5%), breast changes (≤6%), breast disease (children: &lt;2%), breast hypertrophy (children; adults: &lt;5%), breast tenderness (children, adults: ≤7%), cervical neoplasm (children: &lt;2%), cervix disease (children: &lt;2%), decreased prostatic acid phosphatase (≥5%), difficulty in micturition (&lt;2%), dysmenorrhea (children: &lt;2%), dysuria (≤6%), epididymitis (&lt;5%), erectile dysfunction (&lt;2%), hematuria (≤6%), hemorrhagic cystitis (including cystitis: ≤6%), impotence (males: 4% to 5%), increased prostatic acid phosphatase (≥5%), lactation (&lt;5%), mastalgia (≤7%), nocturia (1% to 6%), oliguria (&lt;2%), penile disease (&lt;5%), pollakiuria (2%), prostatic disease (&lt;5%), reduction in penile size (&lt;2%), sexual disorder (accelerated sexual maturity: children: &lt;2%), testicular disease (&lt;5%), testicular pain (2%), urinary frequency (≤6%), urinary incontinence (children, adults: &lt;5%), urinary retention (&lt;2%), urinary tract infection (≤6%), urinary tract obstruction (&lt;5%), urinary tract pain (1%), urinary urgency (≤6%), vaginal discharge (children: ≤3%), vaginal hemorrhage (children: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≤6%), carcinoma (&lt;5%), eosinophilia (≥5%), increased erythrocyte sedimentation rate (children: &lt;2%), leukopenia (≥5%), lymphadenopathy (&lt;5%), lymphedema (&lt;5%), neoplasm (&lt;5%), prolonged partial thromboplastin time (≥5%), prolonged prothrombin time (≥5%), purpuric disease (children: &lt;2%), second primary malignant neoplasm (including basal cell carcinoma of skin, malignant melanoma, non-Hodgkin lymphoma, pulmonary neoplasm), squamous cell carcinoma (7%), thrombocytosis (≥5%), tumor flare (children: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (≥5%), hepatomegaly (&lt;5%), increased gamma-glutamyl transferase (≥5%), increased serum alanine aminotransferase (≥5%), increased serum aspartate aminotransferase (≥5%), increased serum transaminases (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (children, adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Increased ANA titer (children: &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (&lt;5%), herpes zoster infection (&lt;5%), infection (children, adults: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site (children, adults: &lt;3%), injection-site pruritus (≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (&lt;5%), agitation (&lt;5%), altered sense of smell (&lt;2%), amnesia (&lt;5%), anxiety (≤8%), chills (&lt;5%), confusion (&lt;5%), delusion (&lt;5%), dementia (&lt;5%), drowsiness (children: &lt;2%), hypoesthesia (&lt;5%), irritability (including impatience: 2%), loss of consciousness (&lt;5%), memory impairment (6%), nervousness (children: &lt;2%; adults: ≤8%), neuropathy (&lt;5%), numbness (&lt;5%), paralysis (children; adults: &lt;5%), paresthesia (≤8%), peripheral neuropathy (children; adults: &lt;5%), personality disorder (&lt;5%), rigors (&lt;2%), tremor (&lt;2%), voice disorder (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Amyotrophy (&lt;2%), arthralgia (children: &lt;2%; adults: ≤9%), arthritis (≤1%), back pain (children, adults: ≤7%), bone disease (temporal bone swelling: &lt;5%), hyperkinetic muscle activity (children: &lt;2%), limb pain (children, adults: ≤10%), lower limb cramp (≤2%), myalgia (can be severe: children: &lt;2%; adults: ≤8%), myopathy (children: &lt;2%), neck pain (&lt;5%), ostealgia (2% to 5%), pathological fracture (children, adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (&lt;5%), blepharoptosis (&lt;5%), blurred vision (&lt;5%), conjunctivitis (&lt;5%), dry eye syndrome (&lt;5%), visual disturbance (children, adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased urine specific gravity (≥5%), increased blood urea nitrogen, increased serum creatinine, increased urine specific gravity (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (children, adults: &lt;5%), bronchitis (&lt;5%), bronchospasm (children: 6%), chronic obstructive pulmonary disease (5%), dyspnea (≤5%), dyspnea on exertion (1% to 5%), hemoptysis (&lt;5%), hypoxia (&lt;5%), increased bronchial secretions (&lt;5%), paranasal sinus congestion (5%), pharyngitis (children, adults: &lt;5%), pleural effusion (&lt;5%), pleural rub (&lt;5%), pneumonia (&lt;5%), productive cough (children: 6%), pulmonary edema (&lt;5%), pulmonary emphysema (&lt;5%), pulmonary fibrosis (&lt;5%), rhinitis (children, adults: &lt;5%), sinus headache (≤8%), sinusitis (children, adults: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Abnormal healing (&lt;5%), cyst (&lt;5%), inflammation (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Obesity (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, decreased appetite (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Exacerbation of hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hematoma at injection site (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (children)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all populations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aortic aneurysm (ruptured), carotid stenosis, chest tightness, extrasystoles</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperkeratosis, spider telangiectasia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium, galactorrhea not associated with childbirth (females), hyperkalemia, increased libido, increased testosterone level, pituitary insufficiency (suppression of pituitary-gonadal system), thyroid nodule</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Occult blood in stools, rectal fistula, rectal irritation (erythema)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Blisters on penis, increased post-void residual urine volume, penile swelling, pyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hypoproteinemia, leukocytosis, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, facial swelling</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site (including stinging), skin ulceration at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anosmia, burning sensation of feet, cerebrovascular accident, euphoria, hyperreflexia, hyporeflexia, motor dysfunction, spinal cord compression, transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Ankylosing spondylitis, bone fracture (including spinal) (Shahinian 2005), knee effusion, muscle cramps, muscle rigidity, muscle tenderness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eyelid edema, retinal vascular disease (perivascular cuffing)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance (including decreased hearing)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis, pyelonephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Abnormal breath sounds (decreased), dry throat, pleuritic chest pain, pulmonary infiltrates, rales, rhonchi, streptococcal pharyngitis, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fibrosis (pelvic), mass</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all populations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis, prolonged QT interval on ECG (Abbasi 2020), pulmonary embolism, torsades de pointes (Abbasi 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis, exfoliative dermatitis, hypertrichosis, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria (Okdemir 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus with hyperosmolar coma (Saad 2022), pituitary apoplexy (Fabiano 2016; Tanios 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Adenoma (pituitary), decreased white blood cell count</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatotoxicity, hepatic impairment, severe hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Fujisaki 2012), angioedema (Kirkgoz 2020), hypersensitivity angiitis (Gnanaraj 2010), nonimmune anaphylaxis, serum sickness (Gnanaraj 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site granuloma (Yasukawa 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fibromyalgia syndrome, intracranial hypertension (including idiopathic intracranial hypertension) (Tan 2019), mania (Pong 2014), outbursts of anger (Chavez 2010), seizure (Akaboshi 2000), suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (Dawood 1995; Kaya 2015; Smith 2006), muscle spasm, slipped capital femoral epiphysis, tenosynovitis (symptoms)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease (interstitial pneumonitis) (Villalba-Cuesta 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Nodule (throat)</p></div>
<div class="block coi drugH1Div" id="F187436"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to leuprolide, GnRH, GnRH-agonist analogs, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Fensolvi, Lupron-Depot-Ped: Additional contraindications: pregnancy.</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot 3.75 mg (monthly) and Lupron Depot 11.25 mg (3-month): Additional contraindications: patients with undiagnosed uterine bleeding; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Canadian labeling: Additional contraindications (not in US labeling): Patients who are or who could become pregnant; breastfeeding. Zeulide Depot (Canadian product) is also contraindicated in females.</p></div>
<div class="block war drugH1Div" id="F187418"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic syndrome: Metabolic changes (such as hyperglycemia, diabetes, hyperlipidemia) may occur; nonalcoholic fatty liver disease, including cirrhosis, has also been reported. Hyperglycemia may manifest as new-onset diabetes or worsening of glycemic control in patients with preexisting diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: Pseudotumor cerebri (idiopathic intracranial hypertension) has been reported in pediatric patients receiving GnRH agonists, including leuprolide acetate, but is very rare (Omar 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Asthma exacerbations have been reported with therapy in patients with histories of asthma, sinusitis, or environmental or drug allergies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Central precocious puberty: Children treated for precocious puberty may experience signs and symptoms of puberty, including vaginal bleeding, during the first weeks of treatment or after subsequent doses due to the initial stimulatory effect of leuprolide before suppression occurs; health care provider should be notified if symptoms continue after the second month.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Monitor for new or worsening depression, especially in patients with a history of depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: Due to the physiologic effects of the drug, exacerbation of endometriosis symptoms may occur after the first dose of leuprolide.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depot formulations: Vehicle used in injectable (polylactide-co-glycolide microspheres) has rarely been associated with retinal artery occlusion in patients with abnormal arteriovenous anastomosis (eg, patent foramen ovale) (Tang 2007). Do not use a fractional dose of the 3-, 4-, or 6-month depot formulation, or a combination of doses of the monthly depot formulation or any depot formulation due to different release characteristics. The Atrigel delivery system (used in Eligard/Fensolvi) is a nongelatin-based, biodegradable, polymer matrix.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For the treatment of endometriosis, leuprolide can be used in combination with norethindrone acetate (referred to as add-back therapy) to reduce bone mineral density loss and reduce vasomotor symptoms associated with use of leuprolide acetate. Leuprolide in combination with norethindrone acetate (add-back therapy) is not indicated for the preoperative hematologic improvement of patients with anemia caused by heavy menstrual bleeding due to uterine fibroids.</p></div>
<div class="block foc drugH1Div" id="F187429"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intramuscular, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 22.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/0.2 mL</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intramuscular, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (1-Month): 7.5 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (6-Month): 45 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot-Ped (6-Month): 45 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intramuscular, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (1-Month): 3.75 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (3-Month): 11.25 mg, 22.5 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (4-Month): 30 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot-Ped (1-Month): 7.5 mg, 11.25 mg, 15 mg [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot-Ped (3-Month): 30 mg (Ped), 11.25 mg (Ped) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eligard: 7.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eligard: 7.5 mg, 22.5 mg, 30 mg, 45 mg [contains methylpyrrolidone, polylactide-coglycolide]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fensolvi (6 Month): 45 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fensolvi (6 Month): 45 mg [contains methylpyrrolidone, polylactide-coglycolide]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eligard: 30 mg [contains methylpyrrolidone, polylactide-coglycolide]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, Subcutaneous, as mesylate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Camcevi: 42 mg (1 ea) [latex free]</p></div>
<div class="block geq drugH1Div" id="F187414"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F187439"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (Leuprolide Acetate (3 Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg (per each): $1,626.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Eligard Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $542.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg (per each): $1,626.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $2,168.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $3,252.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Fensolvi (6 Month) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $31,363.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Leuprolide Acetate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.2 mL (per each): $808.80 - $891.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot (1-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75 mg (per each): $2,058.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $2,452.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot (3-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11.25 mg (per each): $6,175.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg (per each): $7,358.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot (4-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $9,811.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot (6-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $14,717.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot-Ped (1-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $2,476.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11.25 mg (per each): $4,495.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $4,951.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot-Ped (3-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11.25 mg (per each): $13,486.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $14,854.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lupron Depot-Ped (6-Month) Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $29,709.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Camcevi Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">42 mg (per each): $4,974.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867346"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot: 30 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intramuscular, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (1-Month): 3.75 mg, 7.5 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot (3-Month): 11.25 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron Depot 3 Month Kit: 22.5 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zeulide Depot: 3.75 mg, 22.5 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eligard: 7.5 mg, 22.5 mg, 30 mg, 45 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lupron: 1 mg/0.2 mL ([DSC]) [contains benzyl alcohol]</p></div>
<div class="block admp drugH1Div" id="F52613137"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: <b>Note:</b> Do not use a fractional dose of the 3-, 4-, or 6-month depot formulation, or a combination of doses of the monthly depot formulation or any depot formulation due to different release characteristics. Do not use a combination of syringes to achieve a particular dose. Do not administer IV.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Lupron Depot, Lupron Depot-Ped: Administer as a single injection into the gluteal area, anterior thigh, or deltoid; rotate administration site periodically. Reconstituted solution does not contain preservatives and should be used immediately. Lupron Depot-Ped should be administered by a health care professional.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Long-acting formulation: Fensolvi: Should be administered by a health care professional. Administer as a single SUBQ injection into the abdomen, upper buttocks, or other location with adequate SUBQ tissue that does not have excessive pigment, nodules, lesions, or hair. Avoid areas for injection with brawny or fibrous SUBQ tissue or areas of skin that may be rubbed or compressed (belts or clothing waistband). Rotate injection sites.</p>
<p style="text-indent:-2em;margin-left:4em;">Short-acting formulation: Leuprolide acetate 5 mg/mL solution: Administer undiluted into areas on the arm, thigh, or abdomen; rotate injection site. If an alternate syringe from the manufacturer-provided syringe is required, insulin syringes should be used.</p></div>
<div class="block adm drugH1Div" id="F187433"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Do not use a fractional dose of the 3-, 4-, or 6-month depot formulation, or a combination of doses of the monthly depot formulation or any depot formulation due to different release characteristics. Do not use a combination of syringes to achieve a particular dose. Do not administer IV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Leuprolide Depot (generic, Cipla): Administer as a single injection into the gluteal area, anterior thigh, or deltoid. Injection site should be alternated. Administer immediately after preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot: Must be administered by a health care provider. Administer as a single injection into the gluteal area, anterior thigh, or deltoid. Injection site should be alternated. Administer within 2 hours of preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">Zeulide Depot [Canadian product]: Allow product to reach room temperature before administration. Inject into the upper outer quadrant of the gluteus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Camcevi: Select an injection site in the upper or mid abdominal area with sufficient soft or loose SUBQ tissue that has not been used recently; do not administer into areas with brawny or fibrous SUBQ tissue or locations that could be rubbed or compressed (eg, belt or waistband). Bunch skin around injection site, insert needle at a 90-degree angle to the skin surface, release skin, and slowly and steadily inject full contents; remove needle at the same 90-degree angle. Avoid applying heat directly to the injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Eligard: Vary/rotate injection site; choose site with adequate subcutaneous tissue (eg, upper or mid-abdomen, upper buttocks) that does not have excessive pigment, nodules, lesions, or hair. Avoid areas with brawny or fibrous tissues or areas that may be compressed or rubbed (eg, belt or waistband). Administer within 30 minutes of preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">Leuprolide acetate 5 mg/mL solution (1 mg/0.2 mL): Vary injection site; if an alternate syringe from the syringe provided is required, insulin syringes should be used.</p></div>
<div class="block hazard drugH1Div" id="F49132789"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F187449"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Camcevi: Store at 2°C to 8°C (36°F to 46°F); excursions permitted to 25°C (77°F) for up to 6 days. Do not freeze. Do not shake. Store in original carton to protect from light. Allow to sit at room temperature for 30 minutes prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Eligard, Fensolvi: Store at 2°C to 8°C (36°F to 46°F). Allow to reach room temperature prior to using. Once outside the refrigerator, the kit may be stored (in its original packaging) at 15°C to 30°C (59°F to 86°F) for up to 8 weeks prior to mixing and administration. Once mixed, must be administered within 30 minutes (discard if not used within 30 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide Depot (generic, Cipla): Store at room temperature of 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Upon reconstitution, the suspension does not contain a preservative and should be used immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Lupron Depot, Lupron Depot-Ped: Store at room temperature of 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Upon reconstitution, the suspension does not contain a preservative and should be used immediately; discard if not used within 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide acetate 5 mg/mL solution (1 mg/0.2 mL): Store &lt;25°C (&lt;77°F). Do not freeze. Protect from light and store vial in carton until use.</p>
<p style="text-indent:-2em;margin-left:2em;">Zeulide Depot [Canadian product]: Store at &lt;25°C (&lt;77°F); do not freeze. Administer immediately after reconstitution.</p></div>
<div class="block meg drugH1Div" id="F50133906"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information, and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Fensolvi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F213150s002lbl.pdf%23page%3D15&amp;token=SfMgJEyvqXE70jhw2Ed7wOK%2B7k0BTL1v9A0oyqgGHt896FWf0raAjEK4XelJ7f2j6MCFOX26Vj43I6Rkb8tsCF8j5m%2BIg37jEhquGO6zelsOaL8KPnaO3cg5UsLQey0B&amp;TOPIC_ID=12545" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213150s002lbl.pdf#page=15</a></p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Injection: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F019010s038lbl.pdf%23page%3D27&amp;token=Fd%2FxF91MQ1mzFjjV1nOlWXGbbnJtFM9MrsRSaj%2FLWrGzP1N2V7GbNUvcv7NMZQTDOsGfSPAwB5%2FHtUyEvs2HU6b%2B6G36%2BVXoe%2B7oLvdD2AiXgOFAWuFIIrwhWlgBtzmj&amp;TOPIC_ID=12545" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019010s038lbl.pdf#page=27</a></p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot-Ped: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020263s053lbl.pdf%23page%3D26&amp;token=ovT6oQ1BOnDsz8HX4eSVFhe4nIP806eeSix%2BqoCA%2F86PiwspIWSPPLJW0hDiqHbT3FeZmfKuWRwDmECYVd97qe8yoX%2BQo6T5%2Bg%2B1DFcWNK%2FfLHdgKOb7WpFr1ji6JF1q&amp;TOPIC_ID=12545" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020263s053lbl.pdf#page=26</a></p></div>
<div class="block usep drugH1Div" id="F53567490"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of precocious puberty (Lupron Depot-Ped: FDA approved in children ages ≥1 year; Fensolvi: FDA approved in children ages ≥2 years); management of endometriosis (Lupron Depot 3.75 mg [monthly], Lupron Depot 11.25 mg [3 month]: FDA approved in postmenarchal adolescents); treatment of uterine leiomyomata (fibroids) for preoperative improvement of anemia (Lupron Depot 3.75 mg [monthly], Lupron Depot 11.25 mg [3 month]: FDA approved in postmenarchal adolescents); treatment of advanced prostate carcinoma (Camcevi, Eligard, Lupron Depot [7.5 mg, 22.5 mg, 30 mg, 45 mg], leuprolide solution generic: FDA approved in adults); has also been used as a gonadotropin-releasing hormone (GnRH) agonist stimulation test in female children. <b>Note:</b> Indications vary by product; see product-specific label for details.</p></div>
<div class="block mst drugH1Div" id="F187483"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot (1-month, 3-month, or 6-month formulation) may be confused with Lupron Depot-Ped (1-month, 3-month, or 6-month formulation).</p>
<p style="text-indent:-2em;margin-left:4em;">Lupron Depot-Ped is available in three formulations, a 1-month formulation, a 3-month formulation, and a 6-month formulation. Both the 1-month and 3-month formulations offer an 11.25 mg strength, which may further add confusion.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Leuprolide is available as different salt formulations (leuprolide acetate and leuprolide mesylate). Use caution when selecting a leuprolide formulation, as indications and dosing vary between the products.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299584"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6004203"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Flotufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of ADT on the performance of flotufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Androgen Deprivation Therapy Agents may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact of ADT on the performance of gallium Ga 68 PSMA-11 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Piflufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of ADT on the performance of piflufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307982"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use and throughout treatment in patients who could become pregnant; pregnancy should be excluded prior to use.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment with leuprolide usually inhibits ovulation and stops menstruation; however, contraception is not ensured. When contraception is indicated, a nonhormonal contraceptive should be used during leuprolide therapy.</p>
<p style="text-indent:0em;margin-top:2em;">Leuprolide suppresses ovarian and testicular steroidogenesis. Decreased libido, impotence, erectile dysfunction, and menstrual disorders may result and fertility may be impaired. Suppression of fertility is reversible following discontinuation of leuprolide. Pregnancy rates are not expected to be affected once leuprolide is discontinued. When used to treat pain associated with endometriosis in patients who are infertile, fertility is not improved by leuprolide treatment (ASRM 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Leuprolide is used off label to suppress menstruation and preserve ovarian function and fertility in patients undergoing chemotherapy; however, leuprolide is not considered to be an effective contraceptive; a nonhormonal contraceptive is recommended when leuprolide is used during chemotherapy (ACOG 2018; ACOG 2021).</p></div>
<div class="block pri drugH1Div" id="F187440"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to leuprolide may cause fetal harm. Use is contraindicated during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53567491"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pediatric:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Precocious puberty:</b> Frequency of monitoring may vary by formulation and practice preferences; biochemical measurements do not always correlate with outcomes (Krishna 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Baseline: Luteinizing hormone (LH) (basal or stimulated with a gonadotropin-releasing hormone [GnRH] agonist), sex steroids, bone age assessment (versus chronological age), and growth parameters (height and weight measurements).</p>
<p style="text-indent:-2em;margin-left:6em;">During therapy: GnRH testing (serum LH and follicle-stimulating hormone [FSH] levels) (every 6 to 12 months); testosterone in males and estradiol in females (IM [monthly] and SUBQ short-acting formulations: 1 to 2 months after initiation of therapy and with dosage change; IM [3 month] formulation: 2 to 3 months after initiation of therapy, month 6, and as clinically indicated thereafter; IM [6 month] formulation: 5 to 6 months after initiation of therapy and as clinically appropriate or to confirm maintained efficacy; SUBQ [6 month formulation]: 1 to 2 months after initiation of therapy and as needed to confirm adequate suppression and progression of secondary sexual characteristics); Tanner stage (Sexual Maturity Rating), growth (growth velocity, height [SUBQ short-acting, IM (monthly or 3-month) formulations: every 3 to 6 months; IM (6 month) formulation: every 6 to 12 months]); bone age periodically. Routine or random stimulated measurements of gonadotropins or sex steroids may be used, particularly if suboptimal response; however, FSH levels not typically used (ESPE/LWPES [Carel 2009]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endometriosis:</b> Monitor growth parameters (height, weight, z-scores), BMD (Laufer 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Monitor for hypersensitivity reactions including delayed skin reactions.</p></div>
<div class="block pha drugH1Div" id="F187417"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Leuprolide is an agonist of gonadotropin releasing hormone (GnRH) receptors. Acting as a potent inhibitor of gonadotropin secretion, leuprolide produces an initial increase in luteinizing hormone (LH) and follicle stimulating hormone (FSH), which leads to a transient increase (5 to 12 days [Cook 2000]) in testosterone and dihydrotestosterone (in males) and estrone and estradione (in premenopausal females). Continuous leuprolide administration then results in suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. In males, testosterone levels are reduced to below castrate levels. Leuprolide may also have a direct inhibitory effect on the testes, and act by a different mechanism not directly related to reduction in serum testosterone.</p></div>
<div class="block phk drugH1Div" id="F187435"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Following transient increase, testosterone suppression occurs in ~2 to 4 weeks of continued therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of therapeutic suppression for precocious puberty: Leuprolide: 2 to 4 weeks; Leuprolide depot: 1 month.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Males: V<sub>d</sub>: 27 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 43% to 49%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized to smaller inactive peptides, then may be further catabolized; Major metabolite, pentapeptide (M-1).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 94%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Camcevi: 3.2 hours (first dose) and 2.1 hours (second dose); Eligard: ~5 hours (7.5 mg), ~3.3 hours (30 mg), or ~4.5 hours (45 mg).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;5% as parent and major metabolite).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Camcevi: 7.6 L/hour; Eligard: 8.34 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187441"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Eligard</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Leuproreline sandoz</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lupron | Reliser</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Leuprolide acetato | Lupron</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Leupro sandoz | Leuprone HEXAL</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lupron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Procrin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Procren</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Enantone | Lucrin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Staladex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Daronda</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Agopride | Eurolide | Leuren | Lupride | Luprodex md | Luprofact | Luprorin | Progtase</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Enantone die</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lucrin | Prelar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Leuproreline-Acetaat | Lucrin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lorelina depot | Lupron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Eligard | Leuprolide ace | Leuprolide acetate | Lupron | Lupron depot | Lupron Depot-3 Month | Lupron Depot-4 Month</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Leuprolide | Lucrin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Eligard 1 Month | Eligard 3 Month | Eligard 6 Month</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Leuprorelin sandoz | Lupron | Procren</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lucrin | Prosalid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Leuprolide acetate | Lupro | Lupron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lupron</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lupron</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lucrin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.1">
<a name="HazardousDrugs.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32782861">
<a name="32782861"></a>Abbasi D, Faiek S, Shetty S, Khan E. Shock from twisting peaks: A rare case of recurrent torsades de pointes secondary to leuprolide-induced prolonged QT. <i>Cureus</i>. 2020;12(7):e9041. doi:10.7759/cureus.9041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/32782861/pubmed" id="32782861" target="_blank">32782861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17405996">
<a name="17405996"></a>Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. <i>J Natl Cancer Inst</i>. 2007;99(7):516-525. doi:10.1093/jnci/djk109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17405996/pubmed" id="17405996" target="_blank">17405996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11033292">
<a name="11033292"></a>Akaboshi S, Takeshita K. A case of atypical absence seizures induced by leuprolide acetate. <i>Pediatr Neurol</i>. 2000;23(3):266-268. doi:10.1016/s0887-8994(00)00181-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/11033292/pubmed" id="11033292" target="_blank">11033292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33399429">
<a name="33399429"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Adolescent Health Care. Options for prevention and management of menstrual bleeding in adolescent patients undergoing cancer treatment: ACOG committee opinion, no. 817. <i>Obstet</i>
<i>Gynecol</i>. 2021;137(1):e7-e15. doi:10.1097/AOG.0000000000004209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/33399429/pubmed" id="33399429" target="_blank">33399429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461694">
<a name="30461694"></a>American College of Obstetricians and Gynecologists' (ACOG) committee opinion no. 760: dysmenorrhea and endometriosis in the adolescent. <i>Obstet Gynecol</i>. 2018 Dec;132(6):e249-e258. doi:10.1097/AOG.0000000000002978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/30461694/pubmed" id="30461694" target="_blank">30461694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26831435">
<a name="26831435"></a>Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. <i>Circulation</i>. 2016;133(5):537-541. doi:10.1161/CIRCULATIONAHA.115.012519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26831435/pubmed" id="26831435" target="_blank">26831435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 201420;32(30):3436-3448. doi:10.1200/JCO.2013.54.8404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23930615">
<a name="23930615"></a>Bernad DM, Dal Pra A, Baule C, Frey BN, Faria S. New-onset psychosis following androgen deprivation therapy for prostate cancer. <i>Can J Urol</i>. 2013;20(4):6868-68670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/23930615/pubmed" id="23930615" target="_blank">23930615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10321505">
<a name="10321505"></a>Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. <i>Cancer Chemother Pharmacol</i>. 1999;43(6):461-466. doi:10.1007/s002800050924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/10321505/pubmed" id="10321505" target="_blank">10321505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24918569">
<a name="24918569"></a>Burris K, Ding CY, Lim GF. Leuprolide acetate-induced generalized papular eruption. <i>J Drugs Dermatol</i>. 2014;13(6):755-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/24918569/pubmed" id="24918569" target="_blank">24918569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884586">
<a name="26884586"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. <i>J Clin Oncol</i>. 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26884586/pubmed" id="26884586" target="_blank">26884586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. <i>J Clin Oncol</i>. 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33737254">
<a name="33737254"></a>Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: Recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(8):2968-2982. doi:10.1016/j.jaip.2021.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/33737254/pubmed" id="33737254" target="_blank">33737254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Camcevi.1">
<a name="Camcevi.1"></a>Camcevi (leuprolide mesylate) [prescribing information]. Durham, NC: Accord BioPharma Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19332438">
<a name="19332438"></a>Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. <i>Pediatrics. </i>2009;123(4):752-762. doi:10.1542/peds.2008-1783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19332438/pubmed" id="19332438" target="_blank">19332438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7788009">
<a name="7788009"></a>Carel JC, Lahlou N, Guazzarotti L, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. <i>Eur J Endocrinol</i>. 1995;132(6):699-704. doi:10.1530/eje.0.1320699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/7788009/pubmed" id="7788009" target="_blank">7788009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190641">
<a name="21190641"></a>Chavez B, Reilly T. Manic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric history. <i>J Clin Psychiatry</i>. 2010;71(12):1696-1698. doi:10.4088/JCP.10l06190yel<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/21190641/pubmed" id="21190641" target="_blank">21190641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10794807">
<a name="10794807"></a>Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. <i>Oncologist</i>. 2000;5(2):162-168. doi:10.1634/theoncologist.5-2-162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/10794807/pubmed" id="10794807" target="_blank">10794807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2503724">
<a name="2503724"></a>Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. <i>N Engl J Med</i>. 1989;321(7):419-424. doi:10.1056/NEJM198908173210702. Erratum in:<i> N Engl J Med</i> 1989;321(20):1420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/2503724/pubmed" id="2503724" target="_blank">2503724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17445679">
<a name="17445679"></a>Dangle P, Palit V, Sundaram SK, Weston P. Noninfective cutaneous granuloma with leuprorelin acetate--reality or myth. <i>Urology</i>. 2007;69(4):779.e5-e6. doi:10.1016/j.urology.2007.02.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17445679/pubmed" id="17445679" target="_blank">17445679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7750585">
<a name="7750585"></a>Dawood MY, Ramos J, Khan-Dawood FS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. <i>Fertil Steril</i>. 1995;63(6):1177-1183. doi:10.1016/s0015-0282(16)57593-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/7750585/pubmed" id="7750585" target="_blank">7750585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980944">
<a name="25980944"></a>Di Lauro L, Pizzuti L, Barba M, et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>J Hematol Oncol</i>. 2015;8:53. doi:10.1186/s13045-015-0147-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/25980944/pubmed" id="25980944" target="_blank">25980944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16320157">
<a name="16320157"></a>Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. <i>Exp Clin Endocrinol Diabetes</i>. 2005;113(10):586-592. doi:10.1055/s-2005-865900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/16320157/pubmed" id="16320157" target="_blank">16320157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eligard.1">
<a name="Eligard.1"></a>Eligard (leuprolide acetate) injectable suspension [prescribing information]. Fort Collins, CO: Tolmar Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eligard.3">
<a name="Eligard.3"></a>Eligard (leuprolide acetate) injectable suspension with preconnected syringe system [prescribing information]. Fort Collins, CO: Tomar Therapeutics Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eligard.2">
<a name="Eligard.2"></a>Eligard (leuprolide acetate) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27586180">
<a name="27586180"></a>Fabiano AJ, George S. Pituitary Apoplexy After Initial Leuprolide Injection. <i>World Neurosurg</i>. 2016;95:616.e7-616.e9. doi:10.1016/j.wneu.2016.08.091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/27586180/pubmed" id="27586180" target="_blank">27586180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fensolvi.1">
<a name="Fensolvi.1"></a>Fensolvi (leuprolide acetate) [prescribing information]. Fort Collins, CO: Tolmar; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fensolvi.2">
<a name="Fensolvi.2"></a>Fensolvi (leuprolide acetate) [prescribing information]. Fort Collins, CO: Tolmar Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863451">
<a name="29863451"></a>Francis PA, Pagani O, Fleming GF, et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. <i>N Engl J Med</i>. 2018;379(2):122-137. doi:10.1056/NEJMoa1803164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/29863451/pubmed" id="29863451" target="_blank">29863451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22050405">
<a name="22050405"></a>Fujisaki A, Kondo Y, Goto K, Morita T. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature. <i>Int J Urol</i>. 2012;19(1):81-84. doi:10.1111/j.1442-2042.2011.02886.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/22050405/pubmed" id="22050405" target="_blank">22050405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21798557">
<a name="21798557"></a>Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. <i>J Pediatr</i>. 2011;159(6):982-7.e1. doi:10.1016/j.jpeds.2011.05.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/21798557/pubmed" id="21798557" target="_blank">21798557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635751">
<a name="23635751"></a>Gatti J, Brinker A, Avigan M. Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray). <i>Obstet Gynecol</i>. 2013;121(5):1107. doi:10.1097/AOG.0b013e31828c9cb3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/23635751/pubmed" id="23635751" target="_blank">23635751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26932202">
<a name="26932202"></a>Gava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. <i>Clin Endocrinol (Oxf)</i>. 2016;85(2):239-46. doi:10.1111/cen.13050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26932202/pubmed" id="26932202" target="_blank">26932202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20470239">
<a name="20470239"></a>Gnanaraj J, Saif MW. Hypersensitivity vasculitis associated with leuprolide (<i>Lupron</i>). <i>Cutan Ocul Toxicol</i>. 2010;29(3):224-227. doi:10.3109/15569527.2010.487505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/20470239/pubmed" id="20470239" target="_blank">20470239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19243704">
<a name="19243704"></a>Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. <i>Clin Ther</i>. 2009;31(1):1-31. doi:10.1016/j.clinthera.2009.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19243704/pubmed" id="19243704" target="_blank">19243704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline.<i> J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heger.1999">
<a name="Heger.1999"></a>Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function. <i>J Clin Endocrinol Metab</i>. 1999;84(12):4583-4590.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320642">
<a name="29320642"></a>Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. <i>Endocr Pract</i>. 2017;23(12):1437. doi:10.4158/1934-2403-23.12.1437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/29320642/pubmed" id="29320642" target="_blank">29320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19189683">
<a name="19189683"></a>Houk CP, Kunselman AR, Lee PA. The diagnostic value of a brief GnRH analogue stimulation test in girls with central precocious puberty: a single 30-minute post-stimulation LH sample is adequate. <i>J Pediatr Endocrinol Metab</i>. 2008;21(12):1113-1118. doi:10.1515/jpem.2008.21.12.1113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19189683/pubmed" id="19189683" target="_blank">19189683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31969015">
<a name="31969015"></a>Hu JR, Duncan MS, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: Contemporary meta-analyses. <i>Arterioscler Thromb Vasc Biol</i>. 2020;40(3):e55-e64. doi:10.1161/ATVBAHA.119.313046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31969015/pubmed" id="31969015" target="_blank">31969015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-323. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jaggi.2019">
<a name="Jaggi.2019"></a>Jaggi S, Slone H, Strauss R, Zaeeter W, Pallie V. SUN-421 leuprolide injection induced pituitary apoplexy. <i>J Endocrine Society</i>. 2019;3(suppl 1);SUN-421. https://doi.org/10.1210/js.2019-SUN-421
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26668298">
<a name="26668298"></a>Kaplowitz P, Bloch C; Section on Endocrinology, American Academy of Pediatrics. Evaluation and referral of children with signs of early puberty. <i>Pediatrics</i>. 2016;137(1):10.1542/peds.2015-3732. doi:10.1542/peds.2015-3732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26668298/pubmed" id="26668298" target="_blank">26668298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26360682">
<a name="26360682"></a>Kaya A, Cayir A, Turan MI, Ozkan B. An examination of the effects of leuprolide acetate used in the treatment of central precocious puberty on bone mineral density and 25-hydroxy vitamin D. <i>West Indian Med J</i>. 2015;64(2):104-107. doi:10.7727/wimj.2014.346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26360682/pubmed" id="26360682" target="_blank">26360682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16983113">
<a name="16983113"></a>Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. <i>J Clin Oncol</i>. 2006;24(27):4448-4456. doi:10.1200/JCO.2006.06.2497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/16983113/pubmed" id="16983113" target="_blank">16983113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31972562">
<a name="31972562"></a>Kirkgoz T, Karakoc-Aydiner E, Bugrul F, et al. Management of systemic hypersensitivity reactions to gonadotropin-releasing hormone analogues during treatment of central precocious puberty. <i>Horm Res Paediatr</i>. 2020;93(1):66-72. doi:10.1159/000505329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31972562/pubmed" id="31972562" target="_blank">31972562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37334213">
<a name="37334213"></a>Klein KO, Mauras N, Nayak S, et al. Efficacy and safety of leuprolide acetate 6-month depot for the treatment of central precocious puberty: a phase 3 study. <i>J Endocr Soc</i>. 2023;7(7):bvad071. doi:10.1210/jendso/bvad071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/37334213/pubmed" id="37334213" target="_blank">37334213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28919272">
<a name="28919272"></a>Kluger N, Hahtola S, Lempinen T, Jeskanen L. Cutaneous granulomas caused by subcutaneous injections of leuprorelin acetate. <i>Presse Med</i>. 2017;46(10):966-968. doi:10.1016/j.lpm.2017.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/28919272/pubmed" id="28919272" target="_blank">28919272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31319416">
<a name="31319416"></a>Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. <i>Horm Res Paediatr</i>. 2019;91(6):357-372. doi:10.1159/000501336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31319416/pubmed" id="31319416" target="_blank">31319416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11446201">
<a name="11446201"></a>Krueger RB, Kaplan MS. Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases. <i>Arch Sex Behav</i>. 2001;30(4):409-422. doi:10.1023/a:1010213432606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/11446201/pubmed" id="11446201" target="_blank">11446201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17125443">
<a name="17125443"></a>Lam C, Tjon J, Hamilton J, Ahmet AH. Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. <i>Pharmacotherapy</i>. 2006;26(12):1811-1815. doi:10.1592/phco.26.12.1811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17125443/pubmed" id="17125443" target="_blank">17125443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18936548">
<a name="18936548"></a>Laufer MR. Current approaches to optimizing the treatment of endometriosis in adolescents. <i>Gynecol Obstet Invest</i>. 2008;66(Suppl 1):19-27. doi:10.1159/000148027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/18936548/pubmed" id="18936548" target="_blank">18936548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24926950">
<a name="24926950"></a>Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. <i>J Clin Endocrinol Metab</i>. 2014;99(9):3153-3159. doi: 10.1210/jc.2013-4471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/24926950/pubmed" id="24926950" target="_blank">24926950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1923237">
<a name="1923237"></a>Letterie GS, Stevenson D, Shah A. Recurrent anaphylaxis to a depot form of GnRH analogue. <i>Obstet Gynecol</i>. 1991;78(5 pt 2):943-946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/1923237/pubmed" id="1923237" target="_blank">1923237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AuroMedics.1">
<a name="AuroMedics.1"></a>Leuprolide acetate injection [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; March 2021.</div>
</li>
<li>
<div class="reference">
                  Leuprolide acetate 22.5 mg Mixject (3 Month) [prescribing information]. Warren NJ: Cipla USA Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124128">
<a name="20124128"></a>Levine GN, D'Amico AV, Berger P, et al; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. <i>Circulation</i>. 2010;121(6):833-840. doi:10.1161/CIRCULATIONAHA.109.192695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/20124128/pubmed" id="20124128" target="_blank">20124128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23715580">
<a name="23715580"></a>Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(19):2500-2510. Accessed September 29, 2014. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.49.2678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/23715580/pubmed" id="23715580" target="_blank">23715580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21233692">
<a name="21233692"></a>Lüchinger AB, Mijatovic V, Rustemeyer T, Hompes PG. Anaphylactic reaction to different gonadotropin-releasing hormone agonists for the treatment of endometriosis. <i>Am J Med Sci</i>. 2011;341(3):240-242. doi:10.1097/MAJ.0b013e31820094da<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/21233692/pubmed" id="21233692" target="_blank">21233692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupron.2019.03">
<a name="Lupron.2019.03"></a>Lupron (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupron.2017.05">
<a name="Lupron.2017.05"></a>Lupron (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupron.1">
<a name="Lupron.1"></a>Lupron Depot (leuprolide acetate) [product monograph]. St Laurent, Quebec, Canada: AbbVie Corp; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LupronDepot.2018.12">
<a name="LupronDepot.2018.12"></a>Lupron Depot 1-month 7.5 mg, 3-month 22.5 mg, 4-month 30 mg, 6-month 45 mg (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LupronDepot.2021.02">
<a name="LupronDepot.2021.02"></a>Lupron Depot 3.75 mg (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LupronDepot.2020.03">
<a name="LupronDepot.2020.03"></a>Lupron Depot 3-month 11.25 mg (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LupronDepot.2021.03">
<a name="LupronDepot.2021.03"></a>Lupron Depot-PED (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LupronDepot.2023.04">
<a name="LupronDepot.2023.04"></a>Lupron Depot-PED (leuprolide acetate) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22028996">
<a name="22028996"></a>Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. <i>Indian J Endocrinol Metab</i>. 2011;15(4):261-267. doi:10.4103/2230-8210.85575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/22028996/pubmed" id="22028996" target="_blank">22028996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31188734">
<a name="31188734"></a>Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. <i>J Urol</i>. 2019;202(6):1199-1208. doi:10.1097/JU.0000000000000384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31188734/pubmed" id="31188734" target="_blank">31188734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25517090">
<a name="25517090"></a>McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. <i>Nature</i>. 2015;519(7542):237-241. doi:10.1038/nature14022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/25517090/pubmed" id="25517090" target="_blank">25517090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30879969">
<a name="30879969"></a>Melloni C, Roe MT. Androgen deprivation therapy and cardiovascular disease. <i>Urol Oncol</i>. 2020;38(2):45-52. doi:10.1016/j.urolonc.2019.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/30879969/pubmed" id="30879969" target="_blank">30879969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19302581">
<a name="19302581"></a>Mericq V, Lammoglia JJ, Unanue N, et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. <i>Clin Endocrinol (Oxf)</i>. 2009;71(5):686-690. doi: 10.1111/j.1365-2265.2009.03584.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19302581/pubmed" id="19302581" target="_blank">19302581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23382474">
<a name="23382474"></a>Metzger ML, Meacham LR, Patterson B, et al.. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. <i>J Clin Oncol</i>. 2013;31(9):1239-1247. doi:10.1200/JCO.2012.43.5511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/23382474/pubmed" id="23382474" target="_blank">23382474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28387484">
<a name="28387484"></a>Mitchell BG, Adams AL, Thandi PK. Psychotic exacerbation following subcutaneous leuprolide in a male patient with previous history of schizophrenia. <i>Prim Care Companion CNS Disord</i>. 2017;19(2). doi:10.4088/PCC.16l02038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/28387484/pubmed" id="28387484" target="_blank">28387484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management. Clinical guideline; 2014. https://www.nice.org.uk/guidance/cg183/resources/drug-allergy-diagnosis-and-management-pdf-35109811022821
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25719301">
<a name="25719301"></a>Ökdemir D, Hatipoğlu N, Akar HH, et al. A patient developing anaphylaxis and sensitivity to two different GnRH analogues and a review of literature. <i>J Pediatr Endocrinol Metab</i>. 2015;28(7-8):923-925. doi:10.1515/jpem-2014-0402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/25719301/pubmed" id="25719301" target="_blank">25719301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33896190">
<a name="33896190"></a>Okwuosa TM, Morgans A, Rhee JW, et al; American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Cardiology and the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular Radiology and Intervention. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: Effects and modifications: A scientific statement from the American Heart Association. <i>Circ Genom Precis Med</i>. 2021;14(3):e000082. doi:10.1161/HCG.0000000000000082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/33896190/pubmed" id="33896190" target="_blank">33896190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33292495">
<a name="33292495"></a>Omar AA, Nyaga G, Mungai LNW. Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty. <i>Int J Pediatr Endocrinol</i>. 2020;2020(1):22. doi:10.1186/s13633-020-00092-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/33292495/pubmed" id="33292495" target="_blank">33292495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22568476">
<a name="22568476"></a>Oshima M, Murao K, Ishigami T, Kubo Y. Drug eruption induced by gonadotropin-releasing hormone analogs accompanying radiation-recall phenomenon. <i>J Dermatol</i>. 2012;39(12):1080-1081. doi:10.1111/j.1346-8138.2012.01576.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/22568476/pubmed" id="22568476" target="_blank">22568476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9660431">
<a name="9660431"></a>Palomba S, Affinito P, Tommaselli GA, Nappi C. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. <i>Fertil Steril</i>. 1998;70(1):111-118. doi:10.1016/s0015-0282(98)00128-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/9660431/pubmed" id="9660431" target="_blank">9660431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pong.2014">
<a name="Pong.2014"></a>Pong YH, Lu YC, Tsai VF, Huang PL, Hsieh JT, Chang HC. Acute manic and psychotic symptoms following subcutaneous leuprolide acetate in a male patient without prior psychiatric history: A case report and literature review. 2014;25(1):22-24. https://doi.org/10.1016/j.urols.2013.05.010
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22704630">
<a name="22704630"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Endometriosis and infertility: a committee opinion. <i>Fertil Steril</i>. 2012;98(3):591-598. doi:10.1016/j.fertnstert.2012.05.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/22704630/pubmed" id="22704630" target="_blank">22704630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10986575">
<a name="10986575"></a>Reilly DR, Delva NJ, Hudson RW. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. <i>Can J Psychiatry</i>. 2000;45(6):559-563. doi:10.1177/070674370004500608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/10986575/pubmed" id="10986575" target="_blank">10986575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27217461">
<a name="27217461"></a>Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. <i>J Clin Oncol</i>. 2016;34(25):3069-3103. doi:10.1200/JCO.2016.67.1487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/27217461/pubmed" id="27217461" target="_blank">27217461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35865181">
<a name="35865181"></a>Saad E, Babkir A, Awadelkarim AM, Qureshi F. Leuprolide-induced hyperosmolar hyperglycemic state in an elderly patient: a case report and literature review. <i>Cureus</i>. 2022;14(7):e26993. doi:10.7759/cureus.26993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/35865181/pubmed" id="35865181" target="_blank">35865181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26927501">
<a name="26927501"></a>Sadler Gallagher J, Feldman HA, Stokes NA, et al. The effects of gonadotropin-releasing hormone agonist combined with add-back therapy on quality of life for adolescents with endometriosis: A randomized controlled trial. <i>J Pediatr Adolesc Gynecol</i>. 2017;30(2):215-222. doi:10.1016/j.jpag.2016.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/26927501/pubmed" id="26927501" target="_blank">26927501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25455737">
<a name="25455737"></a>Sasagawa Y, Tachibana O, Nakagawa A, Koya D, Iizuka H. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma. <i>J Clin Neurosci</i>. 2015;22(3):601-603. doi:10.1016/j.jocn.2014.08.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/25455737/pubmed" id="25455737" target="_blank">25455737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20184599">
<a name="20184599"></a>Sathasivam A, Garibaldi L, Shapiro S, Godbold J, Rapaport R. Leuprolide stimulation testing for the evaluation of early female sexual maturation. <i>Clin Endocrinol (Oxf)</i>. 2010;73(3):375-381. doi:10.1111/j.1365-2265.2010.03796.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/20184599/pubmed" id="20184599" target="_blank">20184599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21489559">
<a name="21489559"></a>Sathasivam A, Rosenberg HK, Shapiro S, Wang H, Rapaport R. Pelvic ultrasonography in the evaluation of central precocious puberty: comparison with leuprolide stimulation test. <i>J Pediatr</i>. 2011;159(3):490-495. doi:10.1016/j.jpeds.2011.02.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/21489559/pubmed" id="21489559" target="_blank">21489559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577027">
<a name="17577027"></a>Schmid P, Untch M, Kossé V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. <i>J Clin Oncol</i>. 2007;25(18):2509-2515. doi:10.1200/JCO.2006.08.8534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17577027/pubmed" id="17577027" target="_blank">17577027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12174922">
<a name="12174922"></a>Schmid P, Untch M, Wallwiener D, et al; TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).<i> Anticancer Res</i>. 2002;22(4):2325-2332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/12174922/pubmed" id="12174922" target="_blank">12174922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15647578">
<a name="15647578"></a>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. <i>N Engl J Med</i>. 2005;352(2):154-164. doi:10.1056/NEJMoa041943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/15647578/pubmed" id="15647578" target="_blank">15647578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22882386">
<a name="22882386"></a>Shalin SC, Brantley J, Diwan AH. Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review. <i>J Cutan Pathol</i>. 2012;39(11):1022-1025. doi:10.1111/j.1600-0560.2012.01980.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/22882386/pubmed" id="22882386" target="_blank">22882386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878701">
<a name="17878701"></a>Shiota M, Tokuda N, Kanou T, Yamasaki H. Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer. <i>J Nippon Med Sch</i>. 2007;74(4):306-308. doi:10.1272/jnms.74.306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17878701/pubmed" id="17878701" target="_blank">17878701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062721">
<a name="17062721"></a>Smith MR. Treatment-related osteoporosis in men with prostate cancer. <i>Clin Cancer Res</i>. 2006;12(20 Pt 2):6315s-6319s. doi:10.1158/1078-0432.CCR-06-0846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17062721/pubmed" id="17062721" target="_blank">17062721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20952020">
<a name="20952020"></a>Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. <i>J Urol</i>. 2010;184(6):2313-2319. doi:10.1016/j.juro.2010.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/20952020/pubmed" id="20952020" target="_blank">20952020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16434464">
<a name="16434464"></a>Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. <i>J Clin Endocrinol Metab</i>. 2006;91(4):1305-1308. doi:10.1210/jc.2005-2507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/16434464/pubmed" id="16434464" target="_blank">16434464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19281463">
<a name="19281463"></a>Spry NA, Galvão DA, Davies R, et al. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. <i>BJU Int</i>. 2009;104(6):806-812. doi:10.1111/j.1464-410X.2009.08458.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/19281463/pubmed" id="19281463" target="_blank">19281463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15598675">
<a name="15598675"></a>Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. <i>J Clin Endocrinol Metab</i>. 2005;90(3):1371-1376. doi:10.1210/jc.2004-1863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/15598675/pubmed" id="15598675" target="_blank">15598675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17709768">
<a name="17709768"></a>Tang J, Weiter JJ. Branch retinal artery occlusion after injection of a long-acting risperidone preparation. <i>Ann Intern Med</i>. 2007;147(4):283-284. doi:10.7326/0003-4819-147-4-200708210-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17709768/pubmed" id="17709768" target="_blank">17709768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: A systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28710301">
<a name="28710301"></a>Tanios G, Mungo NA, Kapila A, Bajaj K. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment. <i>BMJ Case Rep</i>. 2017;2017:bcr2016218514. doi:10.1136/bcr-2016-218514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/28710301/pubmed" id="28710301" target="_blank">28710301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32452729">
<a name="32452729"></a>Thibaut F, Cosyns P, Fedoroff JP, et al; WFSBP Task Force on Paraphilias. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. <i>World J Biol Psychiatry</i>. 2020;21(6):412-490. doi:10.1080/15622975.2020.1744723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/32452729/pubmed" id="32452729" target="_blank">32452729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16986003">
<a name="16986003"></a>Thompson IM. Flare associated with LHRH-agonist therapy. <i>Rev Urol</i>. 2001;3 suppl 3(suppl 3):S10-S104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/16986003/pubmed" id="16986003" target="_blank">16986003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2122011">
<a name="2122011"></a>Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.<i> J Urol</i>. 1990;144(6):1479-1480. doi:10.1016/s0022-5347(17)39774-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/2122011/pubmed" id="2122011" target="_blank">2122011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152. Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17964961">
<a name="17964961"></a>Tung YC, Lee JS, Tsai WY, Hsiao PH. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. <i>J Formos Med Assoc</i>. 2007;106(10):826-831. doi:10.1016/S0929-6646(08)60047-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/17964961/pubmed" id="17964961" target="_blank">17964961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. Updated September 2016. Accessed October 5, 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Supplement approval. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/019010Orig1s039ltr.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/019010Orig1s039ltr.pdf</a>. Published July 11, 2017. Accessed August 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35234109">
<a name="35234109"></a>Villalba-Cuesta PL, Álvaro-Vegue C, Carrasco-Muñoz CG, Gomis-Goti C, García-Villa A. Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: a case report. <i>J Oncol Pharm Pract</i>. 2022;28(8):1910-1913. doi:10.1177/10781552221084058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/35234109/pubmed" id="35234109" target="_blank">35234109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31347350">
<a name="31347350"></a>Vurallı D, Alikaşifoğlu A, İyigün İ, et al. Treatment with depot leuprolide acetate in girls with idiopathic precocious puberty: what parameter should be used in deciding on the initial dose?. <i>J Clin Res Pediatr Endocrinol</i>. 2020;12(1):37-44. doi:10.4274/jcrpe.galenos.2019.2019.0060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/31347350/pubmed" id="31347350" target="_blank">31347350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(Suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2933122">
<a name="2933122"></a>Waxman J, Man A, Hendry WF, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. <i>Br Med J (Clin Res Ed)</i>. 1985;291(6506):1387-1388. doi:10.1136/bmj.291.6506.1387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/2933122/pubmed" id="2933122" target="_blank">2933122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15888168">
<a name="15888168"></a>Yasukawa K, Sawamura D, Sugawara H, Kato N. Leuprorelin acetate granulomas: case reports and review of the literature. <i>Br J Dermatol</i>. 2005;152(5):1045-1047. doi:10.1111/j.1365-2133.2005.06341.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leuprolide-pediatric-drug-information/abstract-text/15888168/pubmed" id="15888168" target="_blank">15888168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeulide.1">
<a name="Zeulide.1"></a>Zeulide Depot (leuprolide acetate) [product monograph]. Mississauga, Ontario, Canada: Verity Pharmaceuticals Inc; August 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12545 Version 380.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
